NRXP News - Candlesense

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, today announced its expanded access policy for NRX-100 (pr...

What is the estimated market opportunity and pricing power for a preservative‑free ketamine formulation targeting suicidal ideation in major depressive and bipolar depression patients, and how might this influence NRXP's long‑term revenue outlook? What is the expected timeline for NRX-100 to progress from expanded access to pivotal Phase III trials and potential FDA approval, and how does that compare to competitors' ketamine or rapid‑acting antidepressant programs? How will the expanded access policy and Fast Track designation for NRX-100 affect NRXP's short‑term stock volatility and price target?

Clinical trials

1 day ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NRx Drug Development

What is the expected impact of these results and updates on NRx's valuation and short‑term price action? How does the corporate update, including pipeline progress and partnership announcements, affect NRx's competitive positioning and growth prospects? What are the key financial metrics and any changes in guidance presented in the Q2 2025 results?

Earnings

10 days ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del., Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stag...

How does this timing change align with broader market events or macroeconomic data releases that could affect trading decisions? What is the expected reaction from institutional investors and hedge funds to the new earnings release date? Does the rescheduled conference call suggest new material information will be disclosed, and how should traders position ahead of it?

Earnings

15 days ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression

This designation expands the addressable population for NRX-100 to the 13 million Americans who consider suicide each year and represents a 10x expansion of the addressable population compared to t...

What is the potential effect on analyst coverage, earnings estimates, and consensus recommendations for NRXP? Are there any contingent milestones or milestone‑based financing arrangements that could be triggered by this designation? How does the 10x expansion of the addressable population affect the company's long‑term growth strategy and cash‑flow forecasts?

Regulatory

17 days ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA)

Florida's Agency for Health Care Administration (AHCA) approval is a critical regulatory step toward closing the Dura Medical acquisition Dura Medical, together with previously-announced acquisitio...

How might the market’s perception of NRX’s acquisition strategy influence analyst sentiment and future valuation multiples? Are there any contingent or earn‑out provisions in the Dura Medical deal that could affect future cash flows? What is the potential impact of the acquisitions on NRX’s long‑term growth strategy and competitive positioning within the therapeutic market?

Mergers

20 days ago